Puma Biotech posts Q2 2026 financial results presentation webcast report
Reuters2026/08/06 22:20- Puma Biotechnology webcast on Q2 2026 financial results showed NERLYNX net revenue of USD 53.6 million.
- Net revenue rose about 9% from Q2 2025, up about 28% from Q1 2026.
- Inventory change was -USD 1 million in Q2 2026 versus -USD 1.3 million in Q2 2025.
- Ex-factory bottles sold totaled 2,929, up about 12% from Q2 2025, up about 26% from Q1 2026.
- U.S. commercial demand reached 2,986 bottles, up about 11% from Q2 2025, up about 8% from Q1 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
UBS lowers Ciena target price to $394
EUR/USD Price Forecast: Holds key 100-day SMA at start of the US CPI week
Malaysia Govt Spending Plan Could Help 99 Speed Mart Retail -- Market Talk
Paying the price for supporting the yen? Japan's foreign reserves fell by $87.8 billions in August, possibly due to selling US Treasuries for funding.
Japanese authorities may have used part of their foreign exchange reserves, including foreign securities such as U.S. Treasury bonds, over the past month to fund record-sized foreign exchange intervention operations.
Crypto prices
More
